Combination therapy of analgesics is well suited for pain management especially in elderly patients and, has been recommended by the World Health Organization (WHO). Drug analysis plays an important role in the development, manufacture and therapeutic use of drug. In this study, a suitable, cost effective Isocratic HPLC-UV method (Reversed Phase) has been developed and validated for the simultaneous quantification of Acetaminophen, Caffeine, and Ibuprofen in fixed dose combination drugs, using a mobile phase combination of methanol and 0.025M Phosphate buffer -(adjusted to pH 3.2 with Orthophosphoric acid) in the ratio 85:15.A Vertex ColumnEurospher C 18 (250 x 4.6 mm), flow rate of 1.0 ml/min at 25C were the chromatographic conditions. Darkwah et al.; JAMPS, 20(2): 1-19, 2019; Article no.JAMPS.48110 2 With Piroxicam as internal standard, quantification was achieved with UV detection at 225 nm based on the peak area responses. A good resolution and a short run time (7mins) were achieved with the validated conditions. In consequence, statistical evaluation at the 95% confidence limits revealed that, the method was Linear; with an average correlation coefficient (R = 0.995), and accurate -(mean recovery 99.45% for Acetaminophen, 100.10% for Caffeine and 99.28% for Ibuprofen). With an instrument and intermediate precision RSDs>2.0, the method was found to be specific, Robust, and more economical. Six formulated combination products on the Ghana market were assayed using the validated method. The Acetaminophen, Caffeine and Ibuprofen contents in the combination drugs varied from 97.35% to 103.88%.
INTRODUCTION
Pain is a prevalent symptom experienced by at least 30% of patients undergoing an oncological treatment for metastatic disease and by more than 70% of advanced cancer patients [1] . In 1986 the World Health Organization [2] published a set of guidelines for cancer pain management based on the three step analgesic ladder [2] . Acute or chronic pain relief can be achieved by multifarious methods, with drug use -analgesic, being the mainstay of treatment. However, no single analgesic is perfect and not all pain yields to classic analgesics. Combination therapy of analgesics is well suited for pain management especially in elderly patients and, has been recommended by the World Health Organization (WHO), the American Pain Society (APS) [3] and, the American college of Rheumatology (ACR) [4] . Clinical use of combinations of analgesic drugs has increased considerably in the last few years. The purpose of combining two or more drugs with different mechanisms of action is to achieve a synergistic interaction [1] , yielding a sufficient analgesic effect with lower doses, and, therefore, reducing the intensity and incidence of untoward effects [5] . At present, many diverse classes of drugs serve as an efficient complement to non-steroidal antiinflammatory drugs (NSAIDs), acetaminophen or opioids, in the management of pain. And, at the end, the use of these combinations limits the doses of medication that a patient can receive. The evolution of acute pain therapy has prominently included several combinations of analgesics, including acetaminophen and codeine, acetaminophen and oxycodone, ibuprofen and codeine, and several others. The promise of these combinations is well-known, but so, too, are the potential for adverse events [6] .
The success of analgesic combination drugs depends on the type of pain that is targeted (acute/chronic, inflammatory, neuropathic, cancer), and evidence suggests that, the combination of Acetaminophen also known as Paracetamol, or N-acetyl-p-aminophenol (APAP) and; Ibuprofen has been found to be efficacious in a variety of acute pain states, including postoperative pain, dysmenorrheal and musculoskeletal pain [6, 7] . NSAIDs, such as Ibuprofen, have analgesic, antipyretic and antiinflammatory actions. They inhibit synthesis of prostaglandins by inhibiting cyclo-oxygenase (COX), present as COX-1 and COX-2. Their analgesic and anti-inflammatory effects are a consequence of COX-2 inhibition [8] and, it's safety/efficacy profile is well characterized, and it has a well-established history of use both as a prescription and as an OTC analgesic [9] . In the post codeine world, [10] , the effectiveness of Caffeine (30 mg, 50 mg, 100 mg and 200 mg) as an adjuvant analgesic to Ibuprofen (100 mg or 200 mg) and Acetaminophen has also been evaluated and found to accentuate the potency of Ibuprofen by 140-180% [10] [11] [12] in the Ibuprofen-caffeine combination treatment of postoperative pain after removal of third molars. This has led to the production of multi component analgesics preparations involving Acetaminophen, Ibuprofen and Caffeine by pharmaceutical companies, locally and abroad [13, 14] .
There are at least 40 different combination analgesic preparations involving Acetaminophen and Ibuprofen in different dosages with or without caffeine all over the world [10] , for the management of pain, and this demands the need for proper and efficient analytical methods, since the quality of these combination drug therapies cannot be compromised. At present, there is no existing method of assay for a combination of Acetaminophen, Caffeine, and Ibuprofen in a single dose formulation in the official pharmacopoeias. Some papers have described the analysis of Paracetamol, Caffeine and Ibuprofen in combination therapy based on titrimetric and UV-Spectroscopic methods [15] [16] [17] . Few HPLC with UV, and by capillary electrophoresis with conductivity detection methods are also available for the assay of this combination formulation [18, 19] ; however, there is no existing method (RP-HPLC-UV) reported for the analysis of Acetaminophen, Caffeine, and Ibuprofen in a fixed dose formulation using cost effective solvents like methanol and phosphate buffer which will ensconced pharmaceutical manufacturing industries, as afar as routine analysis of raw materials and products are concerned.
Hence, the aim of this study was to develop and validate a suitable and, cost effective HPLC-UV method for the simultaneous quantification of Acetaminophen (APAP), Caffeine and Ibuprofen in fixed dose combination drugs using cost effective solvents according to ICH -Q2R1 [2005] guidelines. A study of several combinations of different solvents and buffer systems, different pH and suitable internal standards for proper quantitation, led to the described analytical conditions giving sharp and well resolved peaks in a short time. Combination products on the Ghana market containing these analgesics were assayed using the validated method.
EXPERIMENTAL

Instrumentation
The HPLC analyses were carried out on a Knauer Advanced Scientific Instrument (Smartline, Germany), which is equipped with Quaternary Smartline Pump 1000, Smartline degasser, Smartline autosampler 3900, Smartline UV-detector 2500, Smartline Manager 5000, Injection and Switching Valves and, an Eurochrome Software. Chromatographic peaks (UV spectra) were electronically integrated (from 190nm to 400nm for peak identification) and recorded with (Knauer) computing integrator. The column used was a Stationary Vertex Column (Eurospher 100 -5C 18 ) -250 x 4.6mm, with precolumn from Knauer (ASI, Germany) maintained at, > 30C.
Noise auto detection of the Eurochrome software: There is a check field for noise detection by the Eurochrome software. When activated, Eurochrome® automatically calculates and sets the optimal minimum peak height and width parameters. 
Reagents and Materials
Placebo materials
Magnesium Stearate (5 mg -Legend Industries, India), Sodium Lauryl sulphate (4 mg -Aarti Industries Ltd., India), Talc (10 mg-Abhishek Organic Pvt. Ltd., India), and Water (qs).
Commercial samples
Commercial samples except Parabru plus TM -(donated by Letap Pharma. Ltd) were purchased from the local market. 18 ) 250 x 4.6 mm reversed phase was used and, column effluent was monitored at 225 nm. All determinations were performed at temperature 25C, pressure < 300 Mpa and wavelength of detection 225nm. The Injection volume was 20 μl with a flow rate of 1.0 ml/min. The sensitivity of the UV -detector was set at 0.1 AUFS (Absorbance Units Full Scale).
Preparation of Standard Solutions
Internal standard preparation
Weigh accurately 0.04 g of piroxicam powder (reference standard) into a 100 ml volumetric flask; dissolve with 20 ml of the mobile phase, shake to mix, and then make up to volume with the same medium to obtain a concentration of 400 μg/ml .
Acetaminophen-caffeine-ibuprofen stan-dard preparation
The entire validation was carried out on formulation products on the Ghana market, which have existing strengths (API's) of Paracetamol -325 mg, Caffeine -30 mg, and Ibuprofen -200 mg.
Approximately 0.1135 g of Acetaminophen, 0.0105 g of caffeine, and 0.07 g of Ibuprofen reference standards were accurately weighed into three different 100 ml volumetric flasks. The powders were dissolved and made up to volume with the mobile phase -(Stock solution). 4 ml each of the above solutions was pipetted and transferred (combined) into a 25 ml volumetric flask. 5 ml of the internal standard (concentration of 80 μg/ml) was added and the entire solution made up to volume with the mobile phase, to obtain a final concentration of 4540 μg/ml of Acetaminophen, 420 μg/ml of Caffeine, and 2800 μg/ml of Ibuprofen.
Placebo preparation
Weigh an amount of placebo equivalent to 0.1820 g of Parabru plus (TM) capsule content into a 50 ml volumetric flask. Add 10 ml of diluent, sonicate for 5 mins, and top up to the mark with the mobile phase. Filter and pipette 2 ml of the solution into a 25 ml volumetric flask, and top up to the mark.
Preparation of buffer (0.025M Orthophosphoric acid pH 3.2)
Approximately 1.75 g of Potassium dihydrogen orthophosphate was weighed into a 500 ml volumetric flask. 100 ml of distilled water was added and shaken to dissolve. The solution was then topped with water to the 500ml mark, and pH adjusted to 3.2 with orthophosphoric acid.
Diluent
The mobile phase was used as the diluent.
Method Validation
Instrument precision/ reproducibility
Five (5) repeated injections of a single homogenous standard solution of the combination drug formulation (AcetaminophenCaffeine-Ibuprofen) with Piroxicam as an internal standard was injected onto the Chromatograph and the Relative Standard Deviation of each compound was calculated.
Specificity
Chromatographic peak precision and spectral purities of Acetaminophen, Caffeine, and Ibuprofen were determined using UV spectra recorded by the smartline UV -detector. In addition, a solution containing a mixture of the tablet excipients was prepared using the sample preparation procedure and injected onto the chromatograph, to ascertain possible interfering peaks.
Linearity and range
Standard solutions containing 4540 μg/ml of Acetaminophen, 420 μg/ml of Caffeine, and 2800 μg/ml of Ibuprofen were prepared in triplicate. Aliquots of these solutions were diluted with the mobile phase to six (6) different concentrations, of Acetaminophen, Caffeine and, Ibuprofen in the assayed range. Solutions of concentration 104 μg/ml, 123.2 μg/ml,181.2 μg/ml, 226 μg/ml, 280 μg/ml and 317 μg/ml of Acetaminophen, 10.2 μg/ml, 11.4 μg/ml, 16.8 μg/ml, 22.0 μg/ml, 27.4 μg/ml and, 31.9 μg/ml of caffeine, and 64 μg/ml, 76 μg/ml, 114 μg/ml, 139 μg/ml, 170 μg/ml, and 210 μg/ml, of Ibuprofen were finally prepared using the mobile phase. Calibration curves for Peak Area Responses against Concentrations (%w/v), were plotted for each compound and the obtained data were subjected to regression analysis.
Intermediate precision
The intra-day precision was evaluated by analyzing six (6) sample solutions (n = 6) at the final concentration of analyses (454 μg/ml of Acetaminophen, 42 μg/ml of Caffeine and 280 μg/ml of Ibuprofen) using Piroxicam as the internal standard (80 μg/ml). Similarly, the interday precision was evaluated in three consecutive days (n = 18) and the Relative standard deviation (R.S.D) was calculated for each component of interest.
Accuracy
By means of standard addition recovery.
Acetaminophen (WHO STD), Caffeine (WHO STD) and, Ibuprofen (WHO STD), were added to a mixture of the tablet excipients and the recovery determined against 75%, 100%, and 125% of the target concentration. Three different concentration levels were prepared, Acetaminophen-(130 μg/ml, 182 μg/ml, and 228 μg/ml), Caffeine-(12.6 μg/ml, 16.8 μg/ml, and 21.0 μg/ml), and Ibuprofen-(84 μg/ml, 112 μg/ml, and 140 μg/ml). At each level samples were prepared in triplicate and the recovery percentage was determined. 
Robustness
Five sample solutions were prepared and analyzed under the established conditions, and by variation of the following analytical parameters: flow rate-(0.8, 1.0, and 1.2 ml/min) of the mobile phase, proportion of methanol in mobile phase-(83%, 85% and 87%), mobile phase pH-(3.0, 3.2, and 3.4) and column temperature-(20C, 25C, and 30C).The Acetaminophen, Caffeine, and Ibuprofen contents were determined for each condition and the data obtained subjected to statistical analysis (ANOVA).
Detection (LOD), and quantitation (LOQ) limits -(Range)
The entire validation was carried out on a formulation product on the Ghana market by Letap Pharmaceuticals Ltd, Accra, Ghana, which has existing strengths (API's) of Paracetamol -325 mg, Caffeine -30 mg, and Ibuprofen -200 mg.
Combined standards were prepared by sequential dilution and injected onto the chromatograph at decreasing concentrations in the range of 45.4 -454 μg/ml of Acetaminophen, 4.2 -42 μg/ml of Caffeine and 28 -280 μg/ml of Ibuprofen. Since Acetaminophen, which has the highest amount (API) present in the formulation, has a better absorption in the adopted wavelength of detection (225 nm) than Caffeine -which incidentally has the lowest amount (API); the minimum detection limits were set with regards to the detection of Caffeine as the sensitivity of the method.
Efficiency of column (number of theoretical plates)
The number of separate layers (Theoretical plates), with regards to the efficiency of the column (Vertex Column (Europher100 -5C 18 ) 250 x 4.6mm used for the method development and validation was also calculated using the formula N = 16( t W ⁄ ) 2 , where N, t and W represent the number of theoretical plates, retention time of the compound, and peak width of the compound's chromatogram respectively.
Tailing factor of chromatographic peaks
The tailing factor for the chromatogram of each component in the formulation product was calculated using the formula:T f = W 0.05 /2f, where W 0.05 is the width of the peak at 5% height, and f is the distance from the peak maximum to the leading edge of the peak, the distance being measured at a point 5% of the peak height from the baseline [21] . 
Analysis of Fixed
RESULTS AND DISCUSSION
The chromatographic conditions were initially determined using a Shim-pack CLC-ODS (6 mm i.d, x 150) column from Shimadzu (Shimadzu, Kyoto, Japan), and various combinations of methanol/phosphate buffer; and methanol/0.05% trifluoroacetic acid (pH and ionic strength modified with orthophosphoric acid), at different flow rates of 0.5, 1.0, 1.5 and 2.0, in order to optimize column capacity factor for good separation and resolution. A wavelength of maximum absorption measurement was also carried out for peak identification in the range 190 -400 nm, by injecting 20 µl standard solutions of acetaminophen, caffeine, and Ibuprofen -quantitative amounts as present in the combined formulation product. The strength of each phosphate buffer or trifluoroacetic acid (different pH) was combined with methanol in disparate proportions, starting with a 50:50 combination and gradually increasing and decreasing the aqueous content while monitoring their respective effects on separation and resolution. Some of the above chromatographic conditions could elute the compounds of interest in both the bulk powders and tablet matrix with reasonable retention times, but not the other samples being considered for internal standards -(Aspirin, Salbutamol and Piroxicam). Some had poor resolution and tailing peaks, whilst others had poor resolution and unduly long run times Thus, the Shimadzu C 18 was substituted with a Vertex C 18 column (Eurospher 100 -250 x. 18 ), (250 x 4.6 mm) with precolumn, were the optimized conditions with Piroxicam as the internal standard. All determinations were performed at temperature 25C, pressure < 300 Mpa and wavelength of detection 225 nm. The Injection volume was 20 μl with a flow rate of 1.0ml/min, and the sensitivity was set at 0.1 AUFS (Absorbance Units Full Scale).
Validation
Instrument precision/reproducibility
Five (5) The column effluents were monitored at 225nm
Linearity
A linear correlation was found between the peak area responses and the concentrations of Acetaminophen, Caffeine and Ibuprofen in the assayed range. The regression coefficient (r) obtained are 0.9960, 0.9910, 9971 for Acetaminophen, Caffeine and Ibuprofen respectively. These regression coefficients (r) were higher than 0.99, which confirmed the linearity of the method. The residual plots were also normally distributed around the zero mark. The regression analysis data and calibrations graphs are presented below.
Residual plots (Calculated from data generated for Linearity)
The analysis of residuals for Acetaminophen, Caffeine and, Ibuprofen in the combination formulation with the tablet excipients showed that the values are scattered randomly around zero, indicating the linearity of the method. See plots below.
Specificity
Peak precision and purity around 99% to 100% were obtained for Acetaminophen, Caffeine and Ibuprofen in the chromatogram of sample solutions (standards) and mixture of standards with tablet excipients. The chromatograms obtained with the mixture showed no interfering peaks in the same retention time for the Acetaminophen, Caffeine and Ibuprofen, indicating that, other compounds such as the excipients do not co-elute with the main peaks. (Fig. 3.), (Fig.4.), and (Fig. 5). 
Repeatability
Six independent weights of Acetaminophen, Caffeine and Ibuprofen (std) at 100% concentration using piroxicam as the internal standards were injected. The RSD on statistical evaluation for the six injections was < 2.0% for all the three components of interest. Relative standard deviations of 1.18%, 1.30%, and 1.06% were obtained for Acetaminophen, caffeine and Ibuprofen respectively.
Accuracy
Acetaminophen (WHO STD), Caffeine (WHO STD), and Ibuprofen (WHO STD) were added to a mixture of the tablet excipients and determined against 75%, 100% and 125% of the target concentration. The mean recoveries of three sets of injections (n = 9) for Acetaminophen, Caffeine and Ibuprofen were 99.43%, 99.84% and 99.28% respectively, indicating the accuracy of the method. 
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7C. Fig. 7 . A, B, and C: Calibration (Linearity) graphs for acetaminophen, caffeine, and ibuprofen in fixed dose combination formulation with tablet excipients, respectively Table 6 . i, ii, and iii Relative Standard Deviation values were less than 2%, indicating the precision of the method.
Robustness
The method was robust with a 2% variation in parameters of the analytical conditions established for the method. The statistical analysis showed no significant difference between results obtained. Hence, the method µg/ml, and 280 µg/ml for the Acetaminophen, Caffeine, and Ibuprofen respectively (Table 4) .
Efficiency of the column
The theoretical plates (N) of the column, with respect to Acetaminophen, Caffeine, and Ibuprofen (Fig. 3) in the fixed dose formulation were 4295, 5565 and, 10319 respectively. All (N) values were above 2000, indicating that, the chromatographic column contains a large number of separate layers, hence efficient.
Tailing factor of chromatographic peaks
The tailing factors for the chromatographic peaks of Acetaminophen, Caffeine, and Ibuprofen were 1.0076, 1.0842, and 1.0091 respectively. All T f values were approximately 1.0, indicating acceptable peak symmetry (Fig. 5) for the chromatograms.
Stability of solutions
Prepared samples (analytes) and Mobile phase are stable over a 72 hour period if stored at room temperature.
Analysis of Fixed Dose Combination Tablets
Fixeddose formulation of tablets/ capsules/ caplets from six different manufacturing companies, both locally and abroad on the local market (Paracetamol-325 mg, Caffeine-30 mg, and, Ibuprofen-200 mg) was analyzed using the validated method with piroxicam as the internal standard. The content of Acetaminophen, caffeine and Ibuprofen in the tablets/Caplets/ capsules varied from 97.0%-104.0%.
CONCLUSION
The developed method showed to be economical and, a suitable technique to quantify analgesic fixed dose combination therapy and; might be employed for quality control analysis. The method is specific for the detection and estimation of the active ingredients. The method is linear in the specified range. It is also precise. The accuracy of the method is also established, hence this method stands validated with respect to ICH Q2 (R1) 2005 guidelines, and that it is fit for use in the analysis of combination formulations of Acetaminophen, Caffeine and, Ibuprofen and other matrices. The Acetaminophen, Caffeine and Ibuprofen formulations assayed with the validated method evinced quality and the right amount of active ingredient per the labelled claim.
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